Sale of generic drugs slows down in 2014

The sales performance of drugs in 2014 was below industry expectations, especially those of generics, flagship national industries. Information gathered by the Brazilian Association of generic drug Industries, a (Pro generics), based on the indicators of the consulting firm IMS Health, indicate that were marketed 871.7 million generic units last year, an increase of 10.6% on 2013. The estimate was that the expansion could reach 15% in the year.
The total sale of drugs (including all categories) amounted to 3.12 billion units, up 7.8% over the previous year. The recipe, in the same period, amounted to r $ 65.8 billion, an increase of 13.3% in 2013. The generic industry revenue was r $ 16.25 billion, 18.5% growth on 2013. Even with an expansion above two digits, Telma Salles, President of Pro generics, claims that the sector has not advanced as was expected. The growth more "thin", she said, reflects the slowdown in the economy last year and more limited access to health care.
Telma believes that in 2015 the industries will have new challenges ahead of us. "I see with concern. Will be a more difficult year, because of the adjustments and credit retraction. " According to her, although the generic industry has not achieved the growth of 15% expected for the year, Telma acknowledges that the generic segment has strong potential for expansion ahead. "With prices on average 60% lower than the reference products (protected by patents), generics earn even more relevance in stagnant economy scenarios and risk of impairment in the income," he says. "Our initial projection was that, upon completing 15 years in Brazil (in 2014), generics accounted for 40% of total sales of medicines, but we ended with 28% stake. The goal now is to reach that mark in five years. "
Ranking
Last year, the national laboratory EMS, Hortolândia, remained in the lead in the sale of medicines and generics. The Deputy leadership in total volume was with Hypermarcas, followed by Sanofi (owner of Medley). If you consider only generics, Sanofi was in second, followed by Hypermarcas.
Sanofi is losing market share in recent years. In the past two years, the company announced two changes of President. Patrice Zagame, who replaced Heraldo Marchezini in 2013, left the company at the end of last year and will be succeeded by the Swiss Pius Hornstein.